Galectin Therapeutics INC Form 4 insider transactions

Director Marc Rubin acquired 60,000 stock options in Galectin Therapeutics, Inc. on January 23, 2025, according to a Form 4 filing.

Director Gilbert S. Omenn reports the acquisition of stock options in Galectin Therapeutics, Inc.

CEO Joel Lewis reports the acquisition of stock options and restricted stock units in Galectin Therapeutics.

Khurram Jamil, Chief Medical Officer of Galectin Therapeutics, reports the acquisition of stock options and restricted stock units.

Kevin D. Freeman, a director at Galectin Therapeutics, acquired 60,000 stock options on January 23, 2025, according to a Form 4 filing.

Director Kary Eldred of Galectin Therapeutics acquired 60,000 stock options on January 23, 2025, according to a Form 4 filing.

Benjamin Carson Sr., a director at Galectin Therapeutics, acquired 60,000 stock options on January 23, 2025, under the company's 2019 Omnibus Equity Incentive Plan.

Jack Callicutt, CFO of Galectin Therapeutics, reports the acquisition of stock options and restricted stock units.

Director Gilbert S. Omenn reports acquisition of 60,000 stock options in Galectin Therapeutics, Inc.

Director Harold H. Shlevin of Galectin Therapeutics acquired 6,500 shares of common stock at a price of $1.16 per share on December 30, 2024.

Chief Medical Officer of Galectin Therapeutics, Khurram Jamil, reports acquisition of 40,000 shares through vesting of restricted stock units and disposition of 13,654 shares under a pre-arranged 10b5-1 trading plan on December 23, 2024.

Galectin Therapeutics' CEO, Joel Lewis, sold 56,000 shares of common stock after the vesting of restricted stock units, while also acquiring the same amount of shares through the vesting.

Galectin Therapeutics' Chief Financial Officer, Jack W. Callicutt, exercised restricted stock units and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Richard A. Zordani Jr., a director at Galectin Therapeutics, purchased 10,000 shares of common stock at $0.8164 per share on December 24, 2024.

Director Eldred Kary reports acquisition of Galectin Therapeutics shares at $0.82 per share, along with holdings in UTMA and trust accounts.

Director Kevin D Freeman reports acquisition of 10,000 shares of Galectin Therapeutics at $0.8134 per share.

Director Eldred Kary reports acquisition of 500 shares of Galectin Therapeutics, increasing direct and indirect holdings.

Director Kevin D. Freeman reports purchasing 1,300 shares of Galectin Therapeutics at $2.64 per share.

Director Kevin D Freeman recently purchased 10,000 shares of Galectin Therapeutics (GALT) common stock at $2.70 per share.

Director Richard A. Zordani Jr. recently increased his holdings in Galectin Therapeutics through a series of open market purchases.

Chief Medical Officer Khurram Jamil reports the acquisition of stock options and restricted stock units in Galectin Therapeutics Inc. on August 1, 2024.

Kary Eldred, a director at Galectin Therapeutics, amended a previous SEC filing to reflect a recent purchase of 400 shares of common stock at $2.39 per share.

Director Eldred Kary of Galectin Therapeutics reports purchasing 400 shares of common stock at $2.39 per share.

Director Kevin D. Freeman of Galectin Therapeutics Inc. reports purchasing 2,500 shares of common stock at $2.3799 per share.

Director Richard A. Zordani Jr. purchased 1,000 shares of Galectin Therapeutics Inc. on April 30, 2024.

Galectin Therapeutics' CEO, Joel Lewis, recently purchased 1,000 shares of common stock at an average price of $3.39.

James Czirr, a director of Galectin Therapeutics, reported the sale of common stock through 10X Fund, LP on April 22 and 23, 2024.

Director Kevin D. Freeman reports purchasing 2,500 shares of Galectin Therapeutics at $2.98 per share, increasing his direct and indirect holdings.

Director Kevin D Freeman reported the acquisition of 2,063 shares of Galectin Therapeutics Inc. common stock on April 9, 2024.

CEO Joel Lewis acquired 152,584 shares of Galectin Therapeutics through deferred stock units to satisfy compensation agreements.